{"title":"Lipid dysregulation in chronic diseases: systems biology and omics perspectives.","authors":"Debashrita Majumder, Debasmita Bhattacharya, Harjot Singh Gill, Mithul Rajeev, Shubham Sharma, Shashi Prakash Dwivedi, Moupriya Nag, Dibyajit Lahiri","doi":"10.1080/00498254.2026.2680076","DOIUrl":null,"url":null,"abstract":"<p><p>1. Lipids are fundamental regulators of cellular structure, energy balance, and signalling, while their dysregulation contributes significantly to the development of chronic diseases.</p><p><p>2. Recent advances in multi-omics technologies, including genomics, transcriptomics, proteomics, metabolomics, lipidomics, and epigenomics, have transformed the investigation of lipid metabolism by enabling high-resolution characterisation of lipid species, metabolic pathways, and regulatory networks.</p><p><p>3. This review emphasises the significance of lipids in chronic metabolic diseases like cardiovascular disease, type 2 diabetes mellitus, metabolic syndrome, non-alcoholic fatty liver disease, neurodegenerative disorders, cancer, and chronic kidney disease.</p><p><p>4. The discovery of various biomarkers of disease conditions <i>via</i> lipidomics analysis includes lipids such as ceramides, oxidised phospholipids, acylcarnitines, and lysophospholipids, which have been implicated in causing inflammation, oxidative stress, mitochondrial dysfunction, and fibrosis.</p><p><p>5. Omics integration can aid in obtaining new perspectives in understanding disease pathophysiology and help in identifying novel therapeutic targets including PCSK9 (Proprotein convertase subtilisin/kexin type 9), ANGPTL3 (Angiopoietin-like 3), and inflammatory lipids. Recent lipidomics platforms like spatial lipidomics and single-cell lipidomics may add value in developing personalised medicine therapies.</p>","PeriodicalId":23812,"journal":{"name":"Xenobiotica","volume":" ","pages":"534-562"},"PeriodicalIF":1.5000,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Xenobiotica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/00498254.2026.2680076","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/31 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
1. Lipids are fundamental regulators of cellular structure, energy balance, and signalling, while their dysregulation contributes significantly to the development of chronic diseases.
2. Recent advances in multi-omics technologies, including genomics, transcriptomics, proteomics, metabolomics, lipidomics, and epigenomics, have transformed the investigation of lipid metabolism by enabling high-resolution characterisation of lipid species, metabolic pathways, and regulatory networks.
3. This review emphasises the significance of lipids in chronic metabolic diseases like cardiovascular disease, type 2 diabetes mellitus, metabolic syndrome, non-alcoholic fatty liver disease, neurodegenerative disorders, cancer, and chronic kidney disease.
4. The discovery of various biomarkers of disease conditions via lipidomics analysis includes lipids such as ceramides, oxidised phospholipids, acylcarnitines, and lysophospholipids, which have been implicated in causing inflammation, oxidative stress, mitochondrial dysfunction, and fibrosis.
5. Omics integration can aid in obtaining new perspectives in understanding disease pathophysiology and help in identifying novel therapeutic targets including PCSK9 (Proprotein convertase subtilisin/kexin type 9), ANGPTL3 (Angiopoietin-like 3), and inflammatory lipids. Recent lipidomics platforms like spatial lipidomics and single-cell lipidomics may add value in developing personalised medicine therapies.
期刊介绍：
Xenobiotica covers seven main areas, including:General Xenobiochemistry, including in vitro studies concerned with the metabolism, disposition and excretion of drugs, and other xenobiotics, as well as the structure, function and regulation of associated enzymesClinical Pharmacokinetics and Metabolism, covering the pharmacokinetics and absorption, distribution, metabolism and excretion of drugs and other xenobiotics in manAnimal Pharmacokinetics and Metabolism, covering the pharmacokinetics, and absorption, distribution, metabolism and excretion of drugs and other xenobiotics in animalsPharmacogenetics, defined as the identification and functional characterisation of polymorphic genes that encode xenobiotic metabolising enzymes and transporters that may result in altered enzymatic, cellular and clinical responses to xenobioticsMolecular Toxicology, concerning the mechanisms of toxicity and the study of toxicology of xenobiotics at the molecular levelXenobiotic Transporters, concerned with all aspects of the carrier proteins involved in the movement of xenobiotics into and out of cells, and their impact on pharmacokinetic behaviour in animals and manTopics in Xenobiochemistry, in the form of reviews and commentaries are primarily intended to be a critical analysis of the issue, wherein the author offers opinions on the relevance of data or of a particular experimental approach or methodology
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
